FRANKFURT, April 21 - AstraZeneca's chief executive warned in an interview with Handelsblatt that Germany may be excluded from launches of some of the Anglo-Swedish group’s upcoming medicines if the country persists with plans to constrain pharmaceutical spending.
According to the newspaper, he said: "When we can’t launch some of those products, it’s really a problem. It’s going to be very hard for us, we’re going to be attacked, but in the end we will have no choice, also because of the pressure in the U.S."
The comments come after Germany's coalition government unveiled a package of measures intended to reform the statutory health insurance system and close a projected funding shortfall of 20 billion euros. Among the proposals is a change to an existing mandatory discount on patented medicines - a mechanism that could become larger and variable, tied to aggregate drug spending and the level of contributions paid into the insurance system.
The AstraZeneca chief criticized that approach, describing the suggested regulation as "a dangerous backward step," the newspaper reported.
He also highlighted external pressures on pricing policy. The article notes that U.S. President Donald Trump has been advocating for lower prescription drug prices in the United States and has sought to align U.S. prices with those paid in other countries through a most-favoured-nation pricing approach. That push has, the report said, led some drugmakers to delay launches of new medicines in Europe. A Reuters report from last month is cited as showing such delays in response to U.S. pricing initiatives.
Addressing the magnitude of the commercial impact, the executive was quoted: "It’s really not a threat. If you look at the mathematics, you realize that the business impact is so big, we have no choice." He warned that, if pressure continues, Europe could increasingly become a region focused on sales operations rather than on research, development and manufacturing for the industry.
Context note - The comments reflect the company's perspective as reported by Handelsblatt and describe potential consequences tied to Germany's proposed health insurance measures and international pricing developments.
Key implications for markets - The debate touches on pharmaceutical pricing, corporate launch strategies, and the geographic distribution of research and production activity, with potential ramifications for the healthcare, pharmaceutical and manufacturing sectors.